Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
1.
Clin Infect Dis ; 73(4): 750, 2021 08 16.
Article in English | MEDLINE | ID: mdl-33508101
2.
Clin Infect Dis ; 68(2): 196-203, 2019 01 07.
Article in English | MEDLINE | ID: mdl-29893798

ABSTRACT

Background: Clostridium difficile-associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with increased morbidity and mortality. We evaluated fidaxomicin for prevention of CDAD in HSCT patients. Methods: In this double-blind study, subjects undergoing HSCT with fluoroquinolone prophylaxis stratified by transplant type (autologous/allogeneic) were randomized to once-daily oral fidaxomicin (200 mg) or a matching placebo. Dosing began within 2 days of starting conditioning or fluoroquinolone prophylaxis and continued until 7 days after neutrophil engraftment or completion of fluoroquinolone prophylaxis/clinically-indicated antimicrobials for up to 40 days. The primary endpoint was CDAD incidence through 30 days after study medication. The primary endpoint analysis counted confirmed CDAD, receipt of CDAD-effective medications (for any indication), and missing CDAD assessment (for any reason, including death) as failures; this composite analysis is referred to as "prophylaxis failure" to distinguish from the pre-specified sensitivity analysis, which counted only confirmed CDAD (by toxin immunoassay or nucleic acid amplification test) as failure. Results: Of 611 subjects enrolled, 600 were treated and analyzed. Prophylaxis failure was similar in fidaxomicin and placebo recipients (28.6% vs 30.8%; difference 2.2% [-5.1, 9.5], P = .278). However, most failures were due to non-CDAD events. Confirmed CDAD was lower in fidaxomicin vs placebo recipients (4.3% vs 10.7%; difference 6.4% [2.2, 10.6], P = .0014). Drug-related adverse events occurred in 15.0% of fidaxomicin recipients and 20.0% of placebo recipients. Conclusions: While no difference was demonstrated between arms in the primary analysis, results of the sensitivity analysis demonstrated that fidaxomicin significantly reduced the incidence of CDAD in HSCT recipients. Clinical Trials Registration: NCT01691248.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clostridioides difficile , Enterocolitis, Pseudomembranous/prevention & control , Fidaxomicin/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Adult , Aged , Double-Blind Method , Enterocolitis, Pseudomembranous/etiology , Enterocolitis, Pseudomembranous/microbiology , Female , Humans , Male , Middle Aged
3.
Clin Infect Dis ; 63(12): 1537-1538, 2016 12 15.
Article in English | MEDLINE | ID: mdl-27941142
4.
Pharmacotherapy ; 36(12): 1281-1289, 2016 12.
Article in English | MEDLINE | ID: mdl-27862113

ABSTRACT

In recent years, Clostridium difficile infection (CDI) has become a global public health threat associated with increased morbidity, mortality, and economic burden, all of which are exacerbated with disease recurrence. Current guidelines informing treatment decisions are largely based on definitions of disease severity at diagnosis, with subjective components not well delineated across treatment algorithms and clinical trials. Furthermore, there is little evidence linking severity at onset to outcome. However, reducing the risk of recurrence may offer both a better outcome for the individual and decreased downstream economic impact. The authors present data supporting the opinion that patients deemed at low risk for recurrence should receive vancomycin (or metronidazole when cost is an issue), while those at higher risk of recurrence would benefit from fidaxomicin treatment. Although further prospective studies are needed, choosing treatment with the goal of preventing recurrent CDI may offer a better guide than disease severity.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clostridioides difficile/drug effects , Clostridium Infections/drug therapy , Algorithms , Clostridioides difficile/isolation & purification , Clostridium Infections/epidemiology , Clostridium Infections/microbiology , Global Health , Humans , Practice Guidelines as Topic , Public Health , Recurrence , Severity of Illness Index
5.
Can J Infect Dis Med Microbiol ; 2016: 8048757, 2016.
Article in English | MEDLINE | ID: mdl-27366179

ABSTRACT

Background. This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials. Methods. Patients received fidaxomicin or vancomycin 1. Patients were assessed for clinical response recurrence of infection and sustained clinical response for 28 days after treatment completion. Patients at increased risk of recurrence were subjected to subgroup analyses. Results. Clinical response rates for fidaxomicin (90.0%) were noninferior to those with vancomycin (92.2%; 95% confidence interval for difference: -7.7, 3.5). However, fidaxomicin-treated patients had lower recurrence (14.4% versus 28.0%, p = 0.001) and higher sustained clinical response (77.1% versus 66.3%, p = 0.016). Compared with vancomycin, fidaxomicin was associated with lower recurrence rates in all subgroups, reaching statistical significance in patients with age ≥ 65 years (16.0% versus 30.9%, p = 0.026), concomitant antibiotic use (16.2% versus 38.7%, p = 0.036), and non-BI strains (11.8% versus 28.3%, p = 0.004). Higher sustained clinical response rates were observed for fidaxomicin compared with vancomycin in all subgroups; this was statistically significant in the non-BI subgroup (82.8% versus 69.1%, p = 0.021). Conclusions. In Canadian patients, fidaxomicin was superior to vancomycin in sustaining clinical response and reducing CDI recurrence.

6.
BMJ Open Gastroenterol ; 2(1): e000028, 2015.
Article in English | MEDLINE | ID: mdl-26462279

ABSTRACT

OBJECTIVE: It has been established that use of proton pump inhibitors (PPIs) is associated with an increased risk of acquiring Clostridium difficile-associated diarrhoea (CDAD). However, it is not known whether the use of PPIs or histamine-2 receptor antagonists (H2RAs) concurrently with CDAD-targeted antibiotic treatment affects clinical response or recurrence rates. DESIGN: In two phase 3 trials, patients with toxin-positive CDAD were randomised to receive fidaxomicin 200 mg twice daily or vancomycin 125 mg four times daily for 10 days. Only inpatients with CDAD (due to complete medication record availability) were included in this post hoc analysis: 701 patients, of whom 446 (64%) used PPIs or H2RAs during study drug treatment or follow-up. Baseline factors that were statistically significant in univariate analyses were analysed in multivariate analyses of effects on clinical response and recurrence. RESULTS: Multivariate analysis showed that leukocytosis, elevated creatinine and hypoalbuminemia, but not PPI or H2RA use, were significant factors associated with poor clinical responses. Treatment group was the single significant predictor of recurrence; the probability of recurrence after fidaxomicin therapy was half that following vancomycin therapy. CONCLUSIONS: Acid-suppressing drugs, used by nearly two-thirds of inpatients with CDAD, did not worsen clinical response or recurrence when used concurrently with fidaxomicin or vancomycin. Therefore, development of CDAD does not require discontinuation of anti-acid treatment in patients who have an indication for continuing PPI or H2RA therapy, such as gastro-oesophageal reflux disease and risk of gastrointestinal bleed.

7.
Clin Infect Dis ; 59 Suppl 2: S66-70, 2014 Sep 15.
Article in English | MEDLINE | ID: mdl-25151480

ABSTRACT

In 1975 John Bartlett began trials investigating the problem of antibiotic-associated diarrhea and pseudomembranous colitis. His work led the discovery of Clostridium difficile and he identified it as the leading cause of hospital-associated infections.


Subject(s)
Anti-Bacterial Agents/adverse effects , Clostridioides difficile/immunology , Cross Infection/microbiology , Diarrhea/microbiology , Enterocolitis, Pseudomembranous/microbiology , Animals , Bacterial Toxins/immunology , Cross Infection/history , Diarrhea/history , Enterocolitis, Pseudomembranous/history , History, 20th Century , Humans
8.
Clin Infect Dis ; 59(2): e10-52, 2014 Jul 15.
Article in English | MEDLINE | ID: mdl-24973422

ABSTRACT

A panel of national experts was convened by the Infectious Diseases Society of America (IDSA) to update the 2005 guidelines for the treatment of skin and soft tissue infections (SSTIs). The panel's recommendations were developed to be concordant with the recently published IDSA guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections. The focus of this guideline is the diagnosis and appropriate treatment of diverse SSTIs ranging from minor superficial infections to life-threatening infections such as necrotizing fasciitis. In addition, because of an increasing number of immunocompromised hosts worldwide, the guideline addresses the wide array of SSTIs that occur in this population. These guidelines emphasize the importance of clinical skills in promptly diagnosing SSTIs, identifying the pathogen, and administering effective treatments in a timely fashion.


Subject(s)
Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/therapy , Soft Tissue Infections/diagnosis , Soft Tissue Infections/therapy , Humans , United States
9.
Clin Infect Dis ; 59(2): 147-59, 2014 Jul 15.
Article in English | MEDLINE | ID: mdl-24947530

ABSTRACT

A panel of national experts was convened by the Infectious Diseases Society of America (IDSA) to update the 2005 guidelines for the treatment of skin and soft tissue infections (SSTIs). The panel's recommendations were developed to be concordant with the recently published IDSA guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections. The focus of this guideline is the diagnosis and appropriate treatment of diverse SSTIs ranging from minor superficial infections to life-threatening infections such as necrotizing fasciitis. In addition, because of an increasing number of immunocompromised hosts worldwide, the guideline addresses the wide array of SSTIs that occur in this population. These guidelines emphasize the importance of clinical skills in promptly diagnosing SSTIs, identifying the pathogen, and administering effective treatments in a timely fashion.


Subject(s)
Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/therapy , Soft Tissue Infections/diagnosis , Soft Tissue Infections/therapy , Humans , United States
10.
J Infect Dis ; 209(9): 1446-51, 2014 May 01.
Article in English | MEDLINE | ID: mdl-24218500

ABSTRACT

Whole-genome sequencing was used to determine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomicin in pivotal phase 3 trials occurred by preventing relapse of the same infection, by preventing reinfection with a new strain, or by preventing both outcomes. Paired isolates of C. difficile were available from 93 of 199 participants with recurrences (28 were treated with fidaxomicin, and 65 were treated with vancomycin). Given C. difficile evolutionary rates, paired samples ≤2 single-nucleotide variants (SNVs) apart were considered relapses, paired samples >10 SNVs apart were considered reinfection, and those 3-10 SNVs apart (or without whole-genome sequences) were considered indeterminate in a competing risks survival analysis. Fidaxomicin reduced the risk of both relapse (competing risks hazard ratio [HR], 0.40 [95% confidence interval {CI}, .25-.66]; P = .0003) and reinfection (competing risks HR, 0.33 [95% CI, 0.11-1.01]; P = .05).


Subject(s)
Aminoglycosides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Clostridioides difficile/genetics , Clostridium Infections/microbiology , Clostridium Infections/prevention & control , Vancomycin/therapeutic use , Clostridioides difficile/isolation & purification , Clostridium Infections/drug therapy , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Double-Blind Method , Drug Resistance, Bacterial , Fidaxomicin , Genome, Bacterial , Humans , Polymorphism, Single Nucleotide , Secondary Prevention , Sequence Analysis, DNA
12.
Am J Nephrol ; 38(1): 1-11, 2013.
Article in English | MEDLINE | ID: mdl-23796582

ABSTRACT

BACKGROUND/AIMS: Patients with chronic kidney disease (CKD) have increased risk for Clostridium difficile infection (CDI) and for subsequent mortality. We determined the effect of CKD on response to treatment for CDI. METHODS: This is a post hoc analysis of two randomized controlled phase 3 trials that enrolled patients with CDI. Patients received either fidaxomicin 200 mg b.i.d. or vancomycin 125 mg q.i.d. for 10 days. Univariate and multivariate analyses compared end points by treatment received and CKD stage. RESULTS: At baseline, 27, 21, and 9% of the patients had stage 2 (60-89 ml/min/1.73 m(2)), stage 3 (30-59), and stage 4 or higher (<30) CKD. Cure rates were similar for normal (91%) and stage 2 CKD (92%), but declined to 80% for stage 3 and to 75% for stage 4 CKD (p < 0.001 for trend). Time to resolution of diarrhea (TTROD) increased with stage 3 and stage 4 CKD. CDI recurrence rates 4 weeks after treatment were 16, 20, 27, and 24% for normal, stage 2, stage 3, and stage 4 or higher CKD, respectively. Mortality increased with CKD stage. In multivariate analyses, stage 3 or higher CKD correlated with lower odds of cure, greater chance of recurrence, and lower odds of sustained response 28 days after treatment. Initial cure rates were similar in the vancomycin or fidaxomicin groups; however, the rate of recurrence was higher following vancomycin treatment independent of renal function. The presence of immunosuppression did not alter this effect. CONCLUSION: Progressive CKD is associated with increased TTROD, lower cure rates, and higher recurrence rates with treatment of CDI.


Subject(s)
Aminoglycosides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Clostridioides difficile , Enterocolitis, Pseudomembranous/drug therapy , Renal Insufficiency, Chronic/complications , Vancomycin/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Clinical Trials, Phase III as Topic , Enterocolitis, Pseudomembranous/complications , Female , Fidaxomicin , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Randomized Controlled Trials as Topic , Severity of Illness Index , Treatment Outcome , Young Adult
13.
J Am Geriatr Soc ; 61(2): 222-30, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23379974

ABSTRACT

OBJECTIVES: To determine the effect of advancing age on the clinical outcomes of Clostridium difficile (CDI) treatment. DESIGN: Regression modeling of results from two double-blind randomized multicenter studies on the treatment of primary and first recurrent cases of CDI to examine for effects of age and study drug on outcomes of cure (resolution of diarrhea), recurrence within 4 weeks of completing successful therapy, and cure without recurrence. SETTING: Participants were randomized into studies in the United States, Canada, and Europe. PARTICIPANTS: Nine hundred ninety-nine individuals with toxin-positive CDI were randomized to receive vancomycin (125 mg 4 times daily) or fidaxomicin (200 mg twice daily) for 10 days. MEASUREMENTS: The effect of advancing age in those aged 18 to 40 years and in 10-year increments thereafter was examined. RESULTS: The model predicts a 17% lower clinical cure, 17% greater recurrence, and 13% lower sustained clinical response by advancing decade than in those younger than 40 (P < .01 each). Clinical cure was similar in the fidaxomicin and vancomycin treatment groups, although fidaxomicin was associated with a more than 50% lower relative risk for recurrence than vancomycin (P < .001). Multivariate regression modeling showed that risk factors accounting for poorer outcomes with advancing age include infection with the BI strain type, inpatient status, renal insufficiency, leukocytosis, hypoalbuminemia, and concomitant medication exposure. CONCLUSION: Measurable and progressive deterioration in CDI treatment outcomes occurred with advancing age in those aged 40 and older, highlighting the need for prevention and treatment strategies. Fidaxomicin treatment was associated with a 60% lower risk of recurrence than vancomycin after adjusting for age, concomitant antibiotics, and C. difficile strain.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clostridioides difficile/isolation & purification , Enterocolitis, Pseudomembranous/drug therapy , Adolescent , Adult , Age Distribution , Age Factors , Aged , Aged, 80 and over , Double-Blind Method , Female , Humans , Male , Middle Aged , Retrospective Studies , Secondary Prevention , Treatment Outcome , Young Adult
14.
Clin Infect Dis ; 55 Suppl 2: S149-53, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22752864

ABSTRACT

Nonsevere Clostridium difficile infection (CDI) and severe CDI, which carries a higher risk than nonsevere CDI for treatment failure and CDI recurrence, are difficult to distinguish at the time of diagnosis. To investigate the prognostic value of 3 markers of severe CDI suggested by recent guidelines (fever, leukocytosis, and renal failure), we used the database of 2 randomized controlled trials, which contained information for 1105 patients with CDI. Leukocytosis (risk ratio [RR], 2.29; 95% confidence interval [CI], 1.63-3.21) and renal failure (RR, 2.52; 95% CI, 1.82-3.50) were associated with treatment failure. Fever, although associated with treatment failure (RR, 2.45; 95% CI, 1.07-5.61), was rare. Renal failure was the only significant predictor of recurrence (RR, 1.45; 95% CI, 1.05-2.02). Different timing of measurements of leukocyte count and serum creatinine level around the CDI diagnosis led to a different severity classification in many cases. In conclusion, both leukocytosis and renal failure are useful predictors, although timing of measurement is important.


Subject(s)
Aminoglycosides/therapeutic use , Clostridioides difficile/pathogenicity , Clostridium Infections/complications , Leukocytosis/etiology , Renal Insufficiency/etiology , Vancomycin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Clostridium Infections/diagnosis , Clostridium Infections/microbiology , Confidence Intervals , Creatine/analysis , Fever/complications , Fidaxomicin , Humans , Leukocyte Count , Leukocytosis/microbiology , Odds Ratio , Prognosis , ROC Curve , Randomized Controlled Trials as Topic , Recurrence , Renal Insufficiency/microbiology , Severity of Illness Index , Time Factors , Treatment Failure
15.
Clin Infect Dis ; 55 Suppl 2: S154-61, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22752865

ABSTRACT

Recurrence of Clostridium difficile infection (CDI) occurs in approximately 25% of successfully treated patients. Two phase 3 randomized, double-blind trials were conducted at 154 sites in the United States, Canada, and Europe to compare fidaxomicin vs vancomycin in treating CDI. Patients with CDI received fidaxomicin 200 mg twice daily or vancomycin 125 mg 4 times daily for 10 days. The primary end point was clinical cure of CDI at end of treatment, and a secondary end point was recurrence during the 28 days following clinical cure. In all, 1164 subjects were enrolled, of which a subgroup of 128 in the per-protocol population had another recent episode of CDI prior to the CDI diagnosis at study enrollment. In the analysis of this subgroup, initial response to therapy was similar for both drugs (>90% cure). However, recurrence within 28 days occurred in 35.5% of patients treated with vancomycin and 19.7% of patients treated with fidaxomicin (-15.8% difference; 95% confidence interval, -30.4% to -0.3%; P = .045). Early recurrence (within 14 days) was reported in 27% of patients treated with vancomycin and 8% of patients treated with fidaxomicin (P = .003). In patients with a first recurrence of CDI, fidaxomicin was similar to vancomycin in achieving a clinical response at end of therapy but superior in preventing a second recurrence within 28 days.


Subject(s)
Aminoglycosides/therapeutic use , Clostridioides difficile/pathogenicity , Clostridium Infections/drug therapy , Vancomycin/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Aminoglycosides/administration & dosage , Anti-Bacterial Agents/therapeutic use , Canada/epidemiology , Clostridioides difficile/drug effects , Clostridium Infections/diagnosis , Clostridium Infections/epidemiology , Clostridium Infections/microbiology , Confidence Intervals , Double-Blind Method , Europe/epidemiology , Feces/microbiology , Female , Fidaxomicin , Humans , Kaplan-Meier Estimate , Male , Metronidazole/pharmacology , Middle Aged , Secondary Prevention , Time Factors , Treatment Outcome , United States/epidemiology , Vancomycin/administration & dosage , Young Adult
16.
Clin Infect Dis ; 55 Suppl 2: S93-103, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22752871

ABSTRACT

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily or vancomycin 125 mg 4 times a day for 10 days. Post hoc exploratory intent-to-treat (ITT) time-to-event analyses were undertaken on the combined study 003 and 004 data, using fixed-effects meta-analysis and Cox regression models. ITT analysis of the combined 003/004 data for 1164 patients showed that fidaxomicin reduced persistent diarrhea, recurrence, or death by 40% (95% confidence interval [CI], 26%-51%; P < .0001) compared with vancomycin through day 40. A 37% (95% CI, 2%-60%; P = .037) reduction in persistent diarrhea or death was evident through day 12 (heterogeneity P = .50 vs 13-40 days), driven by 7 (1.2%) fidaxomicin versus 17 (2.9%) vancomycin deaths at <12 days. Low albumin level, low eosinophil count, and CDI treatment preenrollment were risk factors for persistent diarrhea or death at 12 days, and CDI in the previous 3 months was a risk factor for recurrence (all P < .01). Fidaxomicin has the potential to substantially improve outcomes from CDI.


Subject(s)
Aminoglycosides/therapeutic use , Clostridioides difficile/pathogenicity , Clostridium Infections/drug therapy , Vancomycin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Clostridium Infections/microbiology , Clostridium Infections/mortality , Diarrhea/drug therapy , Diarrhea/microbiology , Eosinophils , Feces/microbiology , Fidaxomicin , Humans , Intention to Treat Analysis , Leukocyte Count , Proportional Hazards Models , Prospective Studies , Randomized Controlled Trials as Topic , Risk Factors , Secondary Prevention
18.
Clin Infect Dis ; 53(5): 440-7, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21844027

ABSTRACT

BACKGROUND: Treatment guidelines recommend stopping all implicated antibiotics at the onset of Clostridium difficile infection (CDI), but many individuals have persistent or new infections necessitating the use of concomitant antibiotics (CAs). We used data from 2 phase 3 trials to study effects of CAs on response to fidaxomicin or vancomycin. METHODS: Subjects with CDI were treated for 10 days with fidaxomicin 200 mg every 12 hours or vancomycin 125 mg every 6 hours, assessed for resolution of symptoms, and followed up for an additional 4 weeks for evidence of recurrence. Rates of cure, recurrence, and global cure (cure without recurrence) were determined for subgroups of subjects defined by CA use and treatment group. RESULTS: CAs were prescribed for 27.5% of subjects during study participation. The use of CAs concurrent with CDI treatment was associated with a lower cure rate (84.4% vs 92.6%; P < .001) and an extended time to resolution of diarrhea (97 vs 54 hours; P < .001). CA use during the follow-up was associated with more recurrences (24.8% vs 17.7%; not significant), and CA administration at any time was associated with a lower global cure rate (65.8% vs 74.7%; P = .005). When subjects received CAs concurrent with CDI treatment, the cure rate was 90.0% for fidaxomicin and 79.4% for vancomycin (P = .04). In subjects receiving CAs during treatment and/or follow-up, treatment with fidaxomicin compared with vancomycin was associated with 12.3% fewer recurrences (16.9% vs 29.2%; P = .048). CONCLUSIONS: Treatment with CAs compromised initial response to CDI therapy and durability of response. Fidaxomicin was significantly more effective than vancomycin in achieving clinical cure in the presence of CA therapy and in preventing recurrence regardless of CA use.


Subject(s)
Aminoglycosides/therapeutic use , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Enterocolitis, Pseudomembranous/drug therapy , Vancomycin/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Clostridioides difficile , Drug Therapy, Combination , Enterocolitis, Pseudomembranous/etiology , Female , Fidaxomicin , Humans , Male , Middle Aged , Young Adult
19.
Int J Food Sci Nutr ; 62(7): 719-24, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21568818

ABSTRACT

The purpose of this secondary analysis was to examine the relationship between protein and essential amino acids (EAAs) intake with the level of muscle mass (MM) independent of the diet. Twenty-one omnivores, 22 ovo-lacto-vegetarians and 20 vegans were recruited. MM (urinary creatinine), dietary intake (5-day dietary records) and biochemical analyses (urinary and plasma sex hormones) were obtained. We observed no significant difference between groups for MM, total EAA intake, leucine, isoleucine, age and body mass index. However, we observed a significant difference between groups for total dietary protein intake and total energy intake. Despite significant differences in total dietary protein, the EAA intake was not different, indicating that neither the amount nor the quality of protein in these diets was a limiting factor in determining the amount of MM. Thus, each of these diet patterns appears adequate to maintain MM.


Subject(s)
Amino Acids, Essential/metabolism , Diet, Vegetarian , Dietary Proteins/metabolism , Energy Intake , Feeding Behavior , Muscle, Skeletal/metabolism , Adult , Amino Acids, Essential/administration & dosage , Creatinine/urine , Diet Records , Female , Humans , Middle Aged , Muscle, Skeletal/anatomy & histology , Organ Size , Postmenopause , Premenopause , United States , Young Adult
20.
Clin Infect Dis ; 50 Suppl 1: S26-33, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-20067390

ABSTRACT

BACKGROUND: The rationale and lessons learned through the evolution of the National Survey for the Susceptibility of Bacteroides fragilis Group from its initiation in 1981 through 2007 are reviewed here. The survey was conceived in 1980 to track emerging antimicrobial resistance in Bacteroides species. METHODS: Data from the last 11 years of the survey (1997-2007), including 6574 isolates from 13 medical centers, were analyzed for in vitro antimicrobial resistance to both frequently used and newly developed anti-anaerobic agents. The minimum inhibitory concentrations of the antibiotics were determined using agar dilution in accordance with Clinical and Laboratory Standards Institute recommendations. RESULTS: The analyses revealed that the carbapenems (imipenem, meropenem, ertapenem, and doripenem) and piperacillin-tazobactam were the most active agents against these pathogens, with resistance rates of 0.9%-2.3%. In the most recent 3 years of the survey (2005-2007), resistance to some agents was shown to depend on the species, such as ampicillin-sulbactam against Bacteroides distasonis (20.6%) and tigecycline against Bacteroides uniformis and Bacteroides eggerthii ( approximately 7%). Very high resistance rates (>50%) were noted for moxifloxacin and trovafloxacin, particularly against Bacteroides vulgatus. During that period of study, non-B. fragilis Bacteroides species had >40% resistance to clindamycin. Metronidazole-resistant Bacteroides strains were also first reported during that period. CONCLUSIONS: In summary, resistance to antibiotics was greater among non-B. fragilis Bacteroides species than among B. fragilis and was especially greater among species with a low frequency of isolation, such as Bacteroides caccae and B. uniformis. The emergence of resistance among the non-B. fragilis Bacteroides species underscores the need for speciation of B. fragilis group isolates and for clinicians to be aware of associations between species and drug resistance.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria, Anaerobic/drug effects , Bacteroides fragilis/drug effects , Bacteroides/drug effects , Drug Resistance, Bacterial , Bacteremia/microbiology , Bacteroides/classification , Bacteroides/isolation & purification , Bacteroides Infections/microbiology , Bacteroides fragilis/isolation & purification , Data Collection , Humans , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...